Jiangsu Topcel-kh Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Topcel-kh Pharmaceutical Co., Ltd., explained in plain language.
-
New weapon tested against aggressive lymphoma that evades standard treatments
Disease control Recruiting nowThis study is testing a new type of CAR-T cell therapy for adults with a specific, difficult-to-treat form of B-cell lymphoma. The cancer in these patients does not have the CD19 marker, making it unresponsive to many existing CAR-T treatments. The main goal of this early-phase t…
Phase: PHASE1 • Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New 'Armored' immune cell therapy tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy for adults whose diffuse large B-cell lymphoma has come back or not responded to other treatments. The therapy uses the patient's own modified immune cells, which are engineered to targ…
Phase: PHASE1 • Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC